Haefliger, Simon

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 14.

Journal Article

Mc Laughlin, Anna M; Hess, Dagmar; Michelet, Robin; Colombo, Ilaria; Haefliger, Simon; Bastian, Sara; Rabaglio, Manuela; Schwitter, Michael; Fischer, Stefanie; Eckhardt, Katrin; Hayoz, Stefanie; Kopp, Christoph; Klose, Marian; Sessa, Cristiana; Stathis, Anastasios; Halbherr, Stefan; Huisinga, Wilhelm; Joerger, Markus; Kloft, Charlotte (2024). Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer chemotherapy and pharmacology, 94(3), pp. 349-360. Springer 10.1007/s00280-024-04679-z

Coan, Michela; Haefliger, Simon; Ounzain, Samir; Johnson, Rory (2024). Targeting and engineering long non-coding RNAs for cancer therapy. Nature Reviews. Genetics, 25(8), pp. 578-595. Natue Publishing Group 10.1038/s41576-024-00693-2

Colombo, Ilaria; Koster, Kira-Lee; Holer, Lisa; Haefliger, Simon; Rabaglio, Manuela; Bastian, Sara; Schwitter, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Mc Laughlin, Anna M; Kloft, Charlotte; Klose, Marian; Halbherr, Stefan; Baumgartner, Christian; Sessa, Cristiana; Stathis, Anastasios; Hess, Dagmar; Joerger, Markus (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European journal of cancer, 201(113588), p. 113588. Elsevier 10.1016/j.ejca.2024.113588

Joerger, Markus; Hundsberger, Thomas; Haefliger, Simon; von Moos, Roger; Hottinger, Andreas F; Kaindl, Thomas; Engelhardt, Marc; Marszewska, Michalina; Lane, Heidi; Roth, Patrick; Stathis, Anastasios (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41(2), pp. 267-275. Springer 10.1007/s10637-023-01336-9

Frehner, Lorenz; Haefliger, Simon; Cerciello, Ferdinando; Grob, Tobias; Schmid, Sabine (2023). Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer. Case reports in oncology, 16(1), pp. 871-877. Karger 10.1159/000533572

Vancura, Adrienne; Gutierrez, Alejandro H; Hennig, Thorben; Pulido-Quetglas, Carlos; Slack, Frank J; Johnson, Rory; Haefliger, Simon (2022). Is Evolutionary Conservation a Useful Predictor for Cancer Long Noncoding RNAs? Insights from the Cancer LncRNA Census 3. Non-Coding RNA, 8(6) MDPI 10.3390/ncrna8060082

Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016

Esposito, Roberta; Polidori, Taisia; Meise, Dominik F; Pulido-Quetglas, Carlos; Chouvardas, Panagiotis; Forster, Stefan; Schaerer, Paulina; Kobel, Andrea; Schlatter, Juliette; Kerkhof, Erik; Roemmele, Michaela; Rice, Emily S.; Zhu, Lina; Lanzós, Andrés; Guillen-Ramirez, Hugo A; Basile, Giulia; Carrozzo, Irene; Vancura, Adrienne; Ullrich, Sebastian; Andrades, Alvaro; ... (2022). Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Cell genomics, 2(9), p. 100171. Elsevier 10.1016/j.xgen.2022.100171

Krebs, Fanny S; Britschgi, Christian; Pradervand, Sylvain; Achermann, Rita; Tsantoulis, Petros; Haefliger, Simon; Wicki, Andreas; Michielin, Olivier; Zoete, Vincent (2022). Structure-based prediction of BRAF mutation classes using machine-learning approaches. Scientific Reports, 12(1), p. 12528. Nature Publishing Group 10.1038/s41598-022-16556-x

Vancura, Adrienne; Lanzós, Andrés; Bosch-Guiteras, Núria; Esteban, Mònica Torres; Gutierrez, Alejandro H; Haefliger, Simon; Johnson, Rory (2021). Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs. NAR cancer, 3(2), zcab013. Oxford University Press 10.1093/narcan/zcab013

Haefliger, Simon; Klebig, Christiane; Schaubitzer, Kerstin; Schardt, Julian; Timchenko, Nikolai; Mueller, Beatrice U; Pabst, Thomas (2011). Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood, 117(22), pp. 5931-40. Washington, D.C.: American Society of Hematology 10.1182/blood-2010-08-304485

Eyholzer, Marianne; Schmid, Sabine; Schardt, Julian A; Haefliger, Simon; Mueller, Beatrice U; Pabst, Thomas (2010). Complexity of miR-223 regulation by CEBPA in human AML. Leukemia research, 34(5), pp. 672-6. Amsterdam: Elsevier 10.1016/j.leukres.2009.11.019

Pabst, Thomas; Eyholzer, Marianne; Haefliger, Simon; Schardt, Julian; Mueller, Beatrice U (2008). Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. Journal of clinical oncology, 26(31), pp. 5088-93. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.16.5563

Seiler, Roland; Rickenbacher, Andreas; Shaw, Sidney; Haefliger, Simon; Balsiger, Bruno M (2008). Role of selective alpha and beta adrenergic receptor mechanisms in rat jejunal longitudinal muscle contractility. Journal of gastrointestinal surgery, 12(6), pp. 1087-93. New York, N.Y.: Springer-Verlag 10.1007/s11605-007-0327-4

This list was generated on Tue Dec 3 18:03:33 2024 CET.
Provide Feedback